Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 8/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3764619 | 0.99 | NPC1 (0.41) | NPC1RAB9AHTR2CDPP4FAAH | |
| SCHEMBL532234 | 0.76 | FAAH (0.55) | NPC1RAB9ADPP4FAAH | |
| SCHEMBL3761077 | 0.74 | NPC1 (0.52) | NPC1RAB9AFAAHCNR2 | |
| SCHEMBL2007027 | 0.72 | FAAH (0.51) | NPC1RAB9ADPP4FAAHCNR2 | |
| SCHEMBL27471290 | 0.72 | SLC6A2 (0.48) | HTR2CGSK3B | |
| SCHEMBL4885307 | 0.71 | PIM1 (0.47) | RAB9AHTR2CGSK3BLATS1 | |
| SCHEMBL4881229 | 0.71 | PIM1 (0.47) | RAB9AHTR2CGSK3BLATS1 | |
| SCHEMBL4881237 | 0.71 | PIM1 (0.47) | RAB9AHTR2CGSK3BLATS1 | |
| SCHEMBL8114282 | 0.71 | RAB9A (0.46) | NPC1RAB9ALATS1 | |
| SCHEMBL17884678 | 0.71 | SLC6A2 (0.57) | HTR2CROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | NPC1 1078/4885RAB9A 1416/4885HTR2C 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.